Idera Pharmaceuticals Inc. (Nasdaq: IDRA) reported upbeat results from an ongoing Phase 1/2 trial of IMO-8400 to treat patients with Waldenstrom's Macroglobulinemia lifting the stock price 52 cents to close at $4.32.
Upbeat study results for Idera Pharmaceuticals
December 07, 2015 at 16:19 PM EST